InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc.verified

INM

Price:

$4.66

Market Cap:

$3.35M

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosyn...[Read more]

Industry

Biotechnology

IPO Date

2014-05-05

Stock Exchange

NASDAQ

Ticker

INM

The ROE as of November 2024 (TTM) for InMed Pharmaceuticals Inc. (INM) is -16230.19%

According to InMed Pharmaceuticals Inc.’s latest financial reports and current stock price. The company's current ROE is -16230.19%. This represents a change of 224.06% compared to the average of -5008.40% of the last 4 quarters.

InMed Pharmaceuticals Inc. (INM) Historical ROE (quarterly & annually)

How has INM ROE performed in the past?

The mean historical ROE of InMed Pharmaceuticals Inc. over the last ten years is -132.60%. The current -16230.19% ROE has changed 12.14% with respect to the historical average. Over the past ten years (40 quarters), INM's ROE was at its highest in in the June 2023 quarter at -2.80%. The ROE was at its lowest in in the September 2024 quarter at -19985.46%.

Quarterly (TTM)
Annual

Average

-132.60%

Median

-110.83%

Minimum

-271.12%

Maximum

-32.53%

InMed Pharmaceuticals Inc. (INM) ROE by Quarter and Year

Discovering the peaks and valleys of InMed Pharmaceuticals Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 257.63%

Maximum Annual ROE = -32.53%

Minimum Annual Increase = -76.75%

Minimum Annual ROE = -271.12%

Quarterly (TTM)
Annual
YearROEChange
2024-83.37%26.83%
2023-65.74%-67.91%
2022-204.88%48.17%
2021-138.28%-13.69%
2020-160.20%122.19%
2019-72.10%121.63%
2018-32.53%-42.07%
2017-56.16%-76.75%
2016-241.58%-10.90%
2015-271.12%257.63%

InMed Pharmaceuticals Inc. (INM) Average ROE

How has INM ROE performed in the past?

The current ROE of InMed Pharmaceuticals Inc. (INM) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-118.00%

5-year avg

-130.49%

10-year avg

-132.60%

InMed Pharmaceuticals Inc. (INM) ROE vs. Peers

How is INM’s ROE compared to its peers?

InMed Pharmaceuticals Inc.’s ROE is less than Quoin Pharmaceuticals, Ltd. (-126.19%), greater than Allarity Therapeutics, Inc. (-328.22%), less than Kiromic BioPharma, Inc. (327.18%), less than Virax Biolabs Group Limited (-115.10%), less than Biodexa Pharmaceuticals Plc (-101.74%), less than SeaStar Medical Holding Corporation (443.82%), less than Virios Therapeutics, Inc. (-130.35%), greater than ZyVersa Therapeutics, Inc. (-25512.50%), greater than Sonnet BioTherapeutics Holdings, Inc. (-398.33%), greater than Revelation Biosciences, Inc. (-311.33%), less than Palisade Bio, Inc. (-148.31%), less than Bright Minds Biosciences Inc. (-58.51%), greater than Tonix Pharmaceuticals Holding Corp. (-163.95%), less than Immix Biopharma, Inc. (-102.10%), less than Phio Pharmaceuticals Corp. (-134.57%), greater than 180 Life Sciences Corp. (-559.06%), greater than Navidea Biopharmaceuticals, Inc. (-173.56%), less than Sigilon Therapeutics, Inc. (-74.73%), greater than NovaBay Pharmaceuticals, Inc. (-1030.19%), greater than GeoVax Labs, Inc. (-809.91%),

Build a custom stock screener for InMed Pharmaceuticals Inc. (INM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like InMed Pharmaceuticals Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

InMed Pharmaceuticals Inc. (INM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like InMed Pharmaceuticals Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is InMed Pharmaceuticals Inc.'s ROE?

How is the ROE calculated for InMed Pharmaceuticals Inc. (INM)?

What is the highest ROE for InMed Pharmaceuticals Inc. (INM)?

What is the 3-year average ROE for InMed Pharmaceuticals Inc. (INM)?

What is the 5-year average ROE for InMed Pharmaceuticals Inc. (INM)?

How does the current ROE for InMed Pharmaceuticals Inc. (INM) compare to its historical average?